L-dopa long-term treatment in Parkinson's disease: age-related side effects.
about
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Age influences magnitude but not duration of response to levodopaThe effect of age of disease onset on neuropsychological performance in Parkinson's disease.The use of dopamine agonists in very elderly patients with Parkinson's disease.The sydney multicentre study of Parkinson's disease: progression and mortality at 10 yearsCognitive impairment in Parkinson's disease.A comprehensive model of health-related quality of life in Parkinson's disease.Behavioral complications of drug treatment of Parkinson's disease.Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease.Improvement in word-fluency performance in Parkinson's disease by administration of electromagnetic fields.The relationship between diabetes mellitus and Parkinson's disease.Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.Clozapine for the treatment of psychosis in Parkinson's disease: a review.Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.A quantitative study of levodopa-induced dyskinesia in Parkinson's disease.Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations.Set-shifting and spatial orientation in patients with Parkinson's disease.Hallucinations in Parkinson disease: neuropsychological study.Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
P2860
Q27021464-3AEC9E61-CA0A-4D34-B64E-919AB8DBBFF0Q33590439-29814025-3AD3-4645-A4AD-DAD7A12CFFC3Q33627343-3D636BDC-FCE6-4639-BF72-5845C01E924CQ33992654-B5CB53A0-BAB2-458F-8989-5243AEBE4106Q35452958-4CF1CED3-BE96-4CCC-8F3E-4EFB8F5A7F95Q36226772-40301612-31E6-45F8-A166-71D6E788783DQ37280767-C2722013-EEA8-4CF2-8080-0B58B8F9C057Q37771070-DD4FBB8E-76B1-4923-8B71-57727A0B6815Q39761733-72A590E8-95BC-4B65-9616-B63D6E0D27DBQ40648997-3F95A36D-2B0F-4979-84A9-7D4BBB314A4DQ40701172-96414C52-851B-401C-9A65-AB875C6C7E3FQ41097155-9DA4D858-9DF1-4F0F-A803-F5F4785DD29BQ41247488-914A0A2B-057B-4B10-A0C1-19CCF089FC56Q42280055-9F6342EB-62EE-422B-A2C7-6BF12CBB2063Q42284787-71003FE5-CD74-4016-950C-BE028750860AQ48859260-BFC6B533-3A11-4978-B3C4-921E9571DF57Q52041651-1B062FFE-7C6E-493F-BD32-0DC3DE47552EQ52056531-8F12F69A-EACE-4F5E-8631-10FD99C80F9FQ53509756-7FC8A869-F4D8-4B80-8D92-07F484C45433
P2860
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@en
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@nl
type
label
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@en
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@nl
prefLabel
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@en
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@nl
P2093
P356
P1433
P1476
L-dopa long-term treatment in Parkinson's disease: age-related side effects.
@en
P2093
P304
P356
10.1212/WNL.33.11.1518
P407
P577
1983-11-01T00:00:00Z